trending Market Intelligence /marketintelligence/en/news-insights/trending/dSNLqZgvlSbB-HQ0uCR4HA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Apellis closes $117.3M common stock offering

Blog

M&A rebound sparks optimism for near-term deal activity

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud


Apellis closes $117.3M common stock offering

Apellis Pharmaceuticals Inc. closed a public offering of 6.9 million common shares priced at $17 each to raise $117.3 million in gross proceeds.

Shares sold include the additional 900,000 stocks underwriters could have bought as part of their overallotment option,

Citigroup, J.P. Morgan and Cowen acted as joint book-running managers for the offering, while Cantor Fitzgerald & Co. acted as lead manager.

Crestwood, Ky.-based Apellis Pharmaceuticals develops therapies for autoimmune and inflammatory diseases.